A significant advance in personalised treatment for NSCLC patients was the identification of lung cancers with Epidermal Growth Factor Receptor (EGFR) gene mutations [5], which benefit from targeted treatments with EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib and osimertinib [6,7], with significantly prolonged progression-free survival compared to standard chemotherapy [8]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.